Literature DB >> 19399032

TMPRSS2-ERG and PTEN loss in prostate cancer.

Jeremy A Squire.   

Abstract

Two studies show that the common recurrent gene fusion between TMPRSS2 and ERG promotes prostate cancer in both mouse and humans when PTEN is concurrently lost. In human prostate cancer, the presence of both these aberrations may be indicative of poor prognosis, suggesting that preclinical therapeutic research should target both of these pathways.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19399032     DOI： 10.1038/ng0509-509

Source DB:  PubMed          Journal:  Nat Genet        ISSN： 1061-4036            Impact factor:   38.330


  10 in total

1.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Authors:  Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan
Journal:  Science       Date:  2005-10-28       Impact factor: 47.728

2.  Screening for prostate cancer.

Authors:  Thomas H Lee; Philip W Kantoff; Mary F McNaughton-Collins
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

3.  Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias.

Authors:  Maisa Yoshimoto; Jean-Claude Cutz; Paulo A S Nuin; Anthony M Joshua; Jane Bayani; Andrew J Evans; Maria Zielenska; Jeremy A Squire
Journal:  Cancer Genet Cytogenet       Date:  2006-09

4.  Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression.

Authors:  B Kwabi-Addo; D Giri; K Schmidt; K Podsypanina; R Parsons; N Greenberg; M Ittmann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

Review 5.  ETS transcription factors and their emerging roles in human cancer.

Authors:  Arun Seth; Dennis K Watson
Journal:  Eur J Cancer       Date:  2005-10-06       Impact factor: 9.162

6.  ETS rearrangements and prostate cancer initiation.

Authors:  Brett S Carver; Jennifer Tran; Zhenbang Chen; Arkaitz Carracedo-Perez; Andrea Alimonti; Caterina Nardella; Anuradha Gopalan; Peter T Scardino; Carlos Cordon-Cardo; William Gerald; Pier Paolo Pandolfi
Journal:  Nature       Date:  2009-02-12       Impact factor: 49.962

7.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.

Authors:  Brett S Carver; Jennifer Tran; Anuradha Gopalan; Zhenbang Chen; Safa Shaikh; Arkaitz Carracedo; Andrea Alimonti; Caterina Nardella; Shohreh Varmeh; Peter T Scardino; Carlos Cordon-Cardo; William Gerald; Pier Paolo Pandolfi
Journal:  Nat Genet       Date:  2009-04-26       Impact factor: 38.330

8.  Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.

Authors:  Maisa Yoshimoto; Anthony M Joshua; Isabela W Cunha; Renata A Coudry; Francisco P Fonseca; Olga Ludkovski; Maria Zielenska; Fernando A Soares; Jeremy A Squire
Journal:  Mod Pathol       Date:  2008-05-23       Impact factor: 7.842

Review 9.  Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee.

Authors:  Scott B Shappell; George V Thomas; Richard L Roberts; Ron Herbert; Michael M Ittmann; Mark A Rubin; Peter A Humphrey; John P Sundberg; Nora Rozengurt; Roberto Barrios; Jerrold M Ward; Robert D Cardiff
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

10.  Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.

Authors:  Jennifer C King; Jin Xu; John Wongvipat; Haley Hieronymus; Brett S Carver; David H Leung; Barry S Taylor; Chris Sander; Robert D Cardiff; Suzana S Couto; William L Gerald; Charles L Sawyers
Journal:  Nat Genet       Date:  2009-04-26       Impact factor: 38.330
  10 in total
  32 in total

Review 1.  [Diagnostic of prostate cancer: conventional and molecular or cell biological methods].

Authors:  M Susani; L Kenner; Z Culig
Journal:  Pathologe       Date:  2009-12       Impact factor: 1.011

2.  ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma.

Authors:  Raymond B Nagle; Amit M Algotar; Connie C Cortez; Katherine Smith; Carol Jones; Ubaradka G Sathyanarayana; Steven Yun; Janice Riley; Dea Nagy; Ryan Dittamore; Bruce Dalkin; Laura Brosh; Gary Pestano
Journal:  Prostate       Date:  2013-05-07       Impact factor: 4.104

Review 3.  The molecular pathology of cancer.

Authors:  Timothy J R Harris; Frank McCormick
Journal:  Nat Rev Clin Oncol       Date:  2010-03-30       Impact factor: 66.675

Review 4.  Prostate cancer: the need for biomarkers and new therapeutic targets.

Authors:  Juliana Felgueiras; Joana Vieira Silva; Margarida Fardilha
Journal:  J Zhejiang Univ Sci B       Date:  2014-01       Impact factor: 3.066

5.  miR-221 Is down-regulated in TMPRSS2:ERG fusion-positive prostate cancer.

Authors:  Aida Gordanpour; Aleksandra Stanimirovic; Robert K Nam; Carlos S Moreno; Christopher Sherman; Linda Sugar; Arun Seth
Journal:  Anticancer Res       Date:  2011-02       Impact factor: 2.480

Review 6.  Emerging critical role of molecular testing in diagnostic genitourinary pathology.

Authors:  George J Netto; Liang Cheng
Journal:  Arch Pathol Lab Med       Date:  2012-04       Impact factor: 5.534

Review 7.  Molecular circuits of solid tumors: prognostic and predictive tools for bedside use.

Authors:  Charles Ferté; Fabrice André; Jean-Charles Soria
Journal:  Nat Rev Clin Oncol       Date:  2010-06-15       Impact factor: 66.675

8.  Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.

Authors:  Stephen J Murphy; Robert J Karnes; Farhad Kosari; B Edgardo R Parilla Castellar; Benjamin R Kipp; Sarah H Johnson; Simone Terra; Faye R Harris; Geoffrey C Halling; Janet L Schaefer Klein; Aqsa Nasir; Eric Bergstrahl; Laureano J Rangel; William R Sukov; George Vasmatzis; John C Cheville
Journal:  Mod Pathol       Date:  2015-11-27       Impact factor: 7.842

9.  The oncogenic transcription factor ERG represses the transcription of the tumour suppressor gene PTEN in prostate cancer cells.

Authors:  Patricia Adamo; Sean Porazinski; Shavanthi Rajatileka; Samantha Jumbe; Rachel Hagen; Man-Kim Cheung; Ian Wilson; Michael R Ladomery
Journal:  Oncol Lett       Date:  2017-08-28       Impact factor: 2.967

10.  Structural and dynamic studies of the transcription factor ERG reveal DNA binding is allosterically autoinhibited.

Authors:  Michael C Regan; Peter S Horanyi; Edward E Pryor; Jessica L Sarver; David S Cafiso; John H Bushweller
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-29       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.